Impact of Clinical Subgroup and Baseline Amyloid PET Centiloid Levels on Occurrence of ARIA in the Lecanemab Phase 3 Clarity AD Study in Early Alzheimer’s Disease (P1-9.007)

To evaluate the frequency of amyloid-related imaging abnormalities due to edema (ARIA-E) and hemosiderin deposition (ARIA-H) in key subgroups of the Clarity AD trial, including by baseline amyloid PET centiloid levels and by clinical subgroup (mild cognitive impairment [MCI] and mild Alzheimer's disease [mAD]).